In VivoIn Vivo’s editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2024. Vote now in the polls belo
Generics BulletinViatris is continuing to back itself to launch a string of high-value complex generic injectables in the US in 2025, after missing its target of launching certain of these products in the back half of
ScripThe big respiratory players will be casting envious glances at the launch of Verona Pharma’s chronic obstructive pulmonary disorder (COPD) drug, Ohtuvayre, which is going from strength to strength. Th
Pink SheetEleven of Viatris’ products have been halted from entering the US after the firm’s oral finished dose manufacturing facility in Indore, India received a US Food and Drug Administration warning letter